Bayer pharmaceuticals head says there's no pipeline problem

LEVERKUSEN, Germany (Reuters) – Bayer is seeking to defend its pharmaceuticals business that will be diluted in importance by the takeover of Monsanto and faces a threat to revenues in 2024 when the blockbuster heart drug Xarelto loses its patent.


Source: Reuters Health

Leave a Reply

Your email address will not be published. Required fields are marked *